ASCO 2019: Kantar reviews results from phase 3 POLO trial

Anna Boudoures from Kantar reviewed the “practice-changing” results of the phase 3 POLO trial of AstraZeneca and Merck & Co’s drug.
02 June 2019
people sun
Get in touch

Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.

Anna Boudoures from Kantar reviews the “practice-changing” results of the phase 3 POLO trial of AstraZeneca and Merck & Co’s drug, as presented at ASCO 2019 in Chicago.

Get in touch

Publications

Over 1500 scientific and peer-reviewed articles to further understanding in health research.
Search the database